We sincerely welcome Dr. Avisek Majumder from UCSF School of Medicine, San Francisco, United States, to join the Editorial Board of Recent Progress in Tumor. His main research focus is to understand how HER3 (a member of the EGRF/HER family of receptor tyrosine kinases) functions in physiologic signaling and how this function is perturbed in cancer cells. In one project, He is doing structure-function studies of HER2 and HER3 in HER2-positive breast cancer to identify new structural features that are critical for signaling so that he can develop a new generation of drugs that are both highly effective and have fewer side effects than the current treatment regimen for these patients. In another project, he is working on the development of novel SynNotch CART cell therapy to target HER2-positive breast tumors. Apart from these, he is also involved with several other projects that are currently going on in his lab. We appreciate Dr. Avisek Majumder for his participation and support.
July 9, 2024